Urogen Pharma (URGN) Reports Q3 Loss, Misses Revenue Estimates
Urogen Pharma (URGN) delivered earnings and revenue surprises of +4.17% and -11.29%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?